sarilumab联合csDMARDs治疗类风湿关节炎的系统综述与网络荟萃分析
该研究通过系统文献综述和网络荟萃分析,比较了皮下注射sarilumab 200mg或150mg每两周一次联合csDMARDs与其他靶向DMARDs联合csDMARDs及安慰剂联合csDMARDs在csDMARD-IR或TNFi-IR类风湿关节炎患者中的疗效与安全性,共纳入53项试验。结果显示,在csDMARD-IR患者中,sarilumab联合csDMARDs在所有结局上优于安慰剂,与大多数靶向DMARDs无显著差异;在TNFi-IR患者中,sarilumab 200mg在部分结局上优于某些药物,安全性相似。
要点
- csDMARD-IR患者中,sarilumab 200mg和150mg联合csDMARDs在所有疗效结局上优于安慰剂。
- sarilumab 200mg在24周mTSS上优于巴瑞替尼2mg、托法替布和certolizumab。
- TNFi-IR患者中,sarilumab 200mg在DAS28<2.6上优于阿巴西普、戈利木单抗、托珠单抗4mg/kg和利妥昔单抗。
核心结论
- 在csDMARD-IR和TNFi-IR(较小网络)患者中,sarilumab联合csDMARDs相比安慰剂联合csDMARDs具有更优疗效和相似安全性。
- sarilumab联合csDMARDs与其他靶向DMARDs联合csDMARDs相比,疗效和安全性至少相似。
研究设计与样本
- 系统文献综述和网络荟萃分析,纳入53项试验,评估24周疗效和安全性结局。
- 研究对象为对csDMARDs或TNFi应答不足的类风湿关节炎患者。
主要发现
- csDMARD-IR:sarilumab 200mg和150mg联合csDMARDs在所有结局上优于安慰剂联合csDMARDs。
- csDMARD-IR:sarilumab 200mg与大多数靶向DMARDs无统计学显著差异,但在24周mTSS上优于巴瑞替尼2mg、托法替布和certolizumab。
- csDMARD-IR:sarilumab 150mg与所有靶向DMARDs相似。
- TNFi-IR:sarilumab 200mg在ACR20/50/70上与阿巴西普、戈利木单抗、托珠单抗4mg和8mg/kg静脉及利妥昔单抗相似,在ACR50和DAS28<2.6上优于巴瑞替尼2mg,在DAS28<2.6上优于阿巴西普、戈利木单抗、托珠单抗4mg/kg静脉及利妥昔单抗。
- TNFi-IR:sarilumab 150mg与靶向DMARDs相似,但在DAS28<2.6上优于巴瑞替尼2mg和利妥昔单抗,在ACR20和DAS28<2.6上劣于托珠单抗8mg。
关键数值与推荐
- 评估结局包括HAQ-DI、mTSS(含52周)、ACR20/50/70、DAS28<2.6、严重感染/严重不良事件(含52周)。
- sarilumab 200mg和150mg每两周一次皮下注射联合csDMARDs。
临床怎么用
- 对于csDMARD-IR的类风湿关节炎患者,sarilumab联合csDMARDs可作为有效的治疗选择。
- 对于TNFi-IR患者,sarilumab联合csDMARDs的疗效与许多其他靶向DMARDs相似,安全性相当。
局限性
- TNFi-IR网络较小。
- 未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare efficacy and safety of subcutaneous sarilumab 200 mg and 150 mg every 2 weeks plus conventional synthetic disease-modifying antirheumatic drugs (+csDMARDs) versus other targeted DMARDs+csDMARDs and placebo+csDMARDs, in inadequate responders to csDMARDs (csDMARD-IR) or tumour necrosis factor α inhibitors (TNFi-IR). METHODS: Systematic literature review and network meta-analyses (NMA) conducted on 24 week efficacy and safety outcomes: Health Assessment Questionnaire Disability Index, modified total sharp score (mTSS, including 52 weeks), American College of Rheumatology (ACR) 20/50/70, European League Against Rheumatism Disease Activity Score 28-joint count erythrocyte sedimentation rate (DAS28)<2.6; serious infections/serious adverse events (including 52 weeks). RESULTS: 53 trials were selected for NMA. csDMARD-IR: Sarilumab 200 mg+csDMARDs and 150 mg+csDMARDs were superior versus placebo+csDMARDs on all outcomes. Against most targeted DMARDs, sarilumab 200 mg showed no statistically significant differences, except superiority to baricitinib 2 mg, tofacitinib and certolizumab on 24 week mTSS. Sarilumab 150 mg was similar to all targeted DMARDs. TNFi-IR: Sarilumab 200 mg was similar to abatacept, golimumab, tocilizumab 4 mg and 8 mg/kg intravenously and rituximab on ACR20/50/70, superior to baricitinib 2 mg on ACR50 and DAS28<2.6 and to abatacept, golimumab, tocilizumab 4 mg/kg intravenously and rituximab on DAS28<2.6. Sarilumab 150 mg was similar to targeted DMARDs but superior to baricitinib 2 mg and rituximab on DAS28<2.6 and inferior to tocilizumab 8 mg on ACR20 and DAS28<2.6. Serious adverse events, including serious infections, appeared similar for sarilumab versus comparators. CONCLUSIONS: Results suggest that in csDMARD-IR and TNFi-IR (a smaller network), sarilumab+csDMARD had superior efficacy and similar safety versus placebo+csDMARDs and at least similar efficacy and safety versus other targeted DMARDs+csDMARDs.
引用
- Choy E, Freemantle N, Proudfoot C, et al. Evaluation of the efficacy and safety of sarilumab combination therapy in patients with rheumatoid arthritis with inadequate response to conventional disease-modifying antirheumatic drugs or tumour necrosis factor α inhibitors: systematic literature review and network meta-analyses. RMD Open. 2019. PMID: 30886733. doi:10.1136/rmdopen-2018-000798
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。